Biotech & Pharma.T.A, Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A,

BIB 69.53

-1.0%

Nov 7 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jibacoa who wrote (2569)	7/12/2010 12:31:35 PM
From: Jibacoa	Read Replies (1) of 3722

TRBN was up 20.24% at 9:33am and is still up 9.92% at present. Volume remains low, but it is > half its ADV.<g> bigcharts.marketwatch.com The stock dropped below the $3 level last month after PFE said that it had decided to discontinue development of PF-05212374, one of the two investigational R.A. drugs on which the companies are collaborating.<g> Although TRU-015 development was discontinued by PFE. The other TRBN's drug candidate for R.A., SBI-087 will still continue on its PII as PFE's PF-05230895 and the companies are still evaluating SRI-087 as a possible treatment for S.L.E. and TRBN also has some other drugs in its pipeline.<g> The ACTAY is $7 The stock nearest resistance is now at the $3 level. TRBN has 3Qs of better revenues and has also been trimming its losses. The ELs for 2010 & 2011 are $1.40 & 1.33 vs. $1.44 in 2009 In May TBRN cut its guidance below its previous estimates. The insiders hold a good % of the stock. It seems that with some good news the stock could get to the $5 level.<g> bigcharts.marketwatch.com Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next